Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Emendo Biotherapeutics


All Data

Filters Filter refresh
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OMNI nuclease

            Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Anges

            Deal Size: $61.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing January 15, 2020


            The funding will accelerate novel OMNI gene editing platform into a broad therapeutic product pipeline.